Lay summaries of clinical trial results

This branch covers the plain-language summary of a clinical trial's results written for the people who took part and for the public, divided by the question a writer faces about it: what it is for, how it differs from the other accessible-language summary types, what the regulation requires and where it stops, what Annex V fixes and leaves to the sponsor, the guidance and templates that fill the gaps, who writes and reviews the summary, how it is structured, what it must say one trial cannot tell, its visual and video forms, drafting it with AI, testing it with readers, translating it, summarising a Phase I trial in healthy volunteers, and summaries for young participants. It leaves the lay documents written before a trial starts to lay information published before a trial starts, the standing patient leaflet to patient education materials, the summary that accompanies or stands beside a journal article to plain language summaries of publications, the lay summary of a grant application to research proposals and grants, the visual as a deliverable in its own right to visual abstracts and other standalone visual formats, and sentence-level plain language to plain language.

• What a lay summary of trial results is for, and who reads it — the purposes beyond compliance, what participants and the public expect, why readers want the results, how their health literacy differs from a regulator's, and where they find the summary
• Telling the accessible-language summary types apart — the regulatory lay summary, the publication's plain language summary and the standalone summary of a publication, their reading levels, and the names that blur them
• What the regulation requires of a lay summary, and where it stops — the EU requirement's scope, deadline, database and consent provisions, its delayed application and low compliance, medical devices, the United States and other countries
• Covering the Annex V items and settling what they leave open — the ten Annex V items, the language, reading level, wording and layout the sponsor settles, avoiding promotion, handling each item, and which endpoints to report and how
• Working from the non-regulatory guidance and templates — the return-of-results guidance and toolkit, the non-profit's pilot summaries, approved lay documents to borrow from, and the Good Lay Summary Practice guidance, how it was agreed and what it left open
• Who writes and reviews a lay summary — why medical writers suit the work, the skills it needs beyond regulatory writing, the editor and reviewers beside the writer, and working with the sponsor
• Structuring a lay summary around the reader's questions — the message before the background, starting from the take-home points, sections headed by the reader's questions, a published summary page by page, and defining the safety terms
• Saying what one trial's results cannot tell the reader — the limits of one trial, its place in the development programme, and the disclaimer that tells readers what to do before changing therapy
• Visual and video formats for a lay summary — what visuals do for comprehension, figures within the summary, the graphical abstract, the video version, and depicting people so readers identify with them
• Using AI to draft a lay summary — what AI offers and where it falls short, inputs and prompts, human review, governance and testing, multi-agent systems, and disclosing AI use
• Testing a lay summary with its readers — which patients to involve for which task, running a patient panel review, what the panels find, and its cost, time and pitfalls
• Translating a lay summary and authoring it locally — translating plain language, the chain of translation, back translation and country review, and writing the summary in the local language instead
• Summarising a Phase I trial in healthy volunteers — why the result is hard to make useful, standard wording across Phase I designs, what each section carries, and the burden against the reader's gain
• Lay summaries for young trial participants — matching the summary to a child's or adolescent's age, results told as a comic, and testing formats with children